GeneDx Holdings Corp Dossier
|
SectorHealth Care IndustryDiagnostics & Research Beta (adjusted)1.64 Intrinsic Value $70.52median of 2 methodsbased on filings through 30 Jun 2026 Market Price $70.96Price as of 1 Oct 2026 Near fair valueIntrinsic value is 1% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $2.1B Enterprise Value $2.2B Shares Outstanding 28.5M diluted Next Earnings Date27 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary GeneDx Holdings Corp. (NASDAQ: WGS) is a global leader in rare disease diagnostics, leveraging its massive clinical genomic dataset (GeneDx Infinity) to drive high-growth exome and genome sequencing. However, the investment thesis has shifted to a cautious 'Hold' following a highly disappointing Q1 2026 earnings report. While core test volumes grew 34% year-over-year, a severe drop in the blended average reimbursement rate (ARR) to $3,300 and underperformance in non-core segments forced management to slash full-year 2026 revenue guidance by 12% to $475M–$490M. Furthermore, a $31.3 million impairment charge on the Fabric Genomics acquisition and a flurry of securities class action lawsuits have introduced significant execution and legal risks. Near-term upside is capped until reimbursement rates stabilize and the path to adjusted profitability is restored. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$74.00 Mean target$90.44 High · most bullish analyst$103.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case materializes if blended ARR continues to deteriorate below $3,300 due to unfavorable mix shifts and persistent payer pushback. Volume growth slows as pediatricians adopt testing slower than expected. Ongoing class action litigation leads to substantial settlement liabilities or prolonged management distraction, and further write-downs are taken on non-core assets, forcing the company to burn through its $171.7 million cash cushion and seek dilutive financing. Base CaseCentral scenario The base case assumes GeneDx successfully navigates its near-term reimbursement headwinds by leveraging its newly launched Exome-to-Genome Reflex product and expanding its sales force across pediatric and NICU channels. Core exome and genome volumes grow by at least 30% in FY 2026, and adjusted gross margins remain stable at approximately 70%. The company achieves positive adjusted net income by late 2026 or early 2027, while legal expenses from the class action lawsuits remain manageable. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |